GAVI & Moderna

GAVI: GAVI, a global vaccine alliance, committed up to $50 million to the Ebola response, contributing to the overall funding for combating the outbreak.

Moderna: Moderna received up to $50 million from CEPI to support the preclinical and early clinical development of its mRNA-based Ebola Bundibugyo vaccine candidate, leveraging its mRNA platform for rapid response.

GAVI: Making its RVSV-ZEBOV vaccine stockpile available for trials and supporting vaccine access. Its role is key in ensuring vaccine availability for the response.

Moderna: Developed an mRNA-based Bundibugyo vaccine candidate, with Phase 1 trials starting in Canada. Its mRNA platform could offer a rapid response to emerging outbreaks.

GAVI: GAVI>>> holds a stockpile of Ebola vaccines and has 2,000 doses already in the Democratic Republic of the Congo>>> for potential trial use.

Moderna: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.

GAVI: GAVI is listed as a partner in the urgent coordination meeting convened by Africa CDC, indicating potential involvement in the response to the Ebola outbreak.

Moderna: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.